In vitro activity of colistin (polymyxin E) against 3,480 isolates of gram-negative bacilli obtained from patients in Canadian hospitals in the CANWARD study, 2007-2008.
The in vitro activity of colistin was evaluated versus 3,480 isolates of gram-negative bacilli using CLSI broth microdilution methods. The MIC(90) of colistin was < or = 2 microg/ml against a variety of clinically important gram-negative bacilli, including Escherichia coli, Klebsiella spp., Enterobacter spp., Acinetobacter baumannii, and Pseudomonas aeruginosa. All multidrug-resistant (n = 76) P. aeruginosa isolates were susceptible to colistin (MIC, < or = 2 microg/ml). These data support a role for colistin in the treatment of infections caused by multidrug-resistant P. aeruginosa.
Walkty
A
A
Health Sciences Centre, Department of Medicine, Winnipeg, Manitoba, Canada R3A 1R9. awalkty@mts.net
DeCorby
M
M
Nichol
K
K
Karlowsky
J A
JA
Hoban
D J
DJ
Zhanel
G G
GG
D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D003091:Colistin / Q000494:pharmacology*; D024901:Drug Resistance, Multiple, Bacterial; D006090:Gram-Negative Bacteria / Q000187:drug effects*; D006801:Humans; D008826:Microbial Sensitivity Tests; D013997:Time Factors
D000900:Anti-Bacterial Agents; D003091:Colistin
Clin Microbiol Infect. 2006 Apr;12(4):315-21
16524407
Clin Infect Dis. 2003 May 1;36(9):1111-8
12715304
Lancet Infect Dis. 2006 Sep;6(9):589-601
16931410
Crit Care. 2003 Oct;7(5):R78-83
12974973
Int J Antimicrob Agents. 2006 Oct;28(4):366-9
16971093
Clin Infect Dis. 2005 May 1;40(9):1333-41
15825037
Int J Infect Dis. 2007 Sep;11(5):402-6
17291803
Intensive Care Med. 2005 Aug;31(8):1058-65
15983759
J Antimicrob Chemother. 1997 Feb;39(2):255-60
9069549
Singapore Med J. 2006 Jul;47(7):621-4
16810437